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Background
BAY 58–2667 is a soluble guanylate cyclase activator that
acts independently of nitric oxide. Preclinical data indi-
cate that BAY 58–2667 induces cyclic guanosine mono-
phosphate (cGMP) generation and vasodilation
preferentially in diseased vessels. This phase I clinical trial
in healthy male volunteers was the first intravenous eval-
uation of BAY 58–2667 in humans.
Materials and methods
This single-site study assessed the safety, tolerability and
pharmacokinetics of intravenously administered BAY 58–
2667 in healthy male volunteers. For initial dose-finding,
BAY582667 was administered for 2 h at doses of 15 μg/h,
45 μg/h and 100 μg/h (n = 2 per dose group). Safety
parameters (adverse events [AEs], electrocardiograms
[ECGs] and standard laboratory values), pharmacody-
namics (heart rate [HR], mean arterial pressure [MAP],
diastolic blood pressure [DBP] and plasma vasoactive
hormone levels) and pharmacokinetics were assessed
using a single-blinded, randomized, placebo-controlled
study design: four doses of BAY 58–2667 (range: 50–200
μg/h) were administered for 2 h or 4 h to six individuals
per dose group, with an additional 250 μg/h dose group
(n = 5) in the 4-h infusion administration group (placebo
groups, n = 7 for the 2-h dose group and n = 10 for the 4-
h dose group).
Results
Sixteen AEs occurring in 12 (20%) of 59 subjects receiving
BAY 58–2667 were attributed to the study compound. All
were of mild intensity, including two cases of mild symp-
tomatic hypotension. There was an increase in the fre-
quency of cardiovascular-related AEs with increasing dose
of the study compound. BAY 58–2667 had no clinically
relevant effects on ECGs or laboratory values. Pharmaco-
dynamic evaluation showed that BAY582667 increased
HR in a dose-dependent manner when infused over 2 h (P
= 0.0002) and 4 h (P < 0.0001). In healthy young subjects,
the cardiovascular system compensates for changes in
blood pressure with changes in HR to keep the blood pres-
sure constant as long as possible. Therefore, HR is consid-
ered the most sensitive non-invasive parameter for
indirect estimation of the effect of a vasodilating agent on
the cardiovascular system. Pharmacodynamic evaluation
also showed that BAY 58–2667 dose-dependently
decreased MAP (2 h: P = 0.0069; 4 h: P = 0.0008) and DBP
(2 h: P = 0.0058; 4 h: P = 0.0004). In terms of vasoactive
hormones, BAY 58–2667 dose-dependently increased
plasma renin activity (2 h: P = 0.0064; 4 h: P = 0.0212),
angiotensin II levels (2 h: P = 0.0042; 4 h: P = 0.0013) and
noradrenalin levels (2 h: P < 0.0001; 4 h: P = 0.0002),
while having no significant effect on plasma aldosterone
levels. Plasma levels of cGMP increased dose-dependently
in the 4-h infusion groups (P < 0.0001), but not the 2-h
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infusion groups (P = 0.7884). BAY 58–2667 pharmacoki-
netics showed low inter-individual variability. Plasma
concentrations correlated closely with doses adminis-
tered, and declined rapidly following the end of infusion.
Conclusion
BAY 58–2667 has a favourable safety profile and was well
tolerated in healthy subjects. It reduced peripheral vascu-
lar resistance by dose-dependently increasing HR and
plasma vasoactive hormones, and decreasing MAP and
DBP. Further studies are warranted to assess the therapeu-
tic potential of BAY 58–2667 in patients with acute
decompensated heart failure and other cardiovascular dis-
eases.Page 2 of 2
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